GlassScriptPhysician profile
Gary Lloyd Massad
NPI 1851509236
$1,684.72
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $612 · 2023: $807 · 2024: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $356.55 | 2022-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $332.54 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $189.19 | 2022-2024 | Uzedy, Austedo |
| Ironshore Pharmaceuticals INC. | $145.60 | 2022-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $130.02 | 2022-2023 | Trintellix |
| Corium, LLC | $108.26 | 2022-2023 | Azstarys |
| Tris Pharma INC | $74.26 | 2022-2023 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $64.19 | 2022-2023 | Spravato |
| Abbvie INC. | $54.78 | 2023 | |
| Lundbeck LLC | $53.83 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.04 | 2022 | |
| Alkermes, INC. | $38.55 | 2023 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $28.88 | 2023 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $24.48 | 2023 | Auvelity |
| Indivior INC. | $17.70 | 2023 | Sublocade |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $15.85 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Massad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.